MTOR and neoplasm: GNE-477, an effective dual PI3K/mTOR inhibitor, has shown satisfactory pharmacokinetic properties in rats, mice and dogs, as well as significant inhibition of PC3 tumor growth in other studies (Zhao et al., 2019).